8. Kaplan–Meier Estimates of the Probability of Survival in the Group Assigned to Receive an Implantable Defibrillator and the Group Assigned to Receive Conventional Medical Therapy. Moss AJ et al. N Engl J Med 2002;346:877-883.
9.
10. Supported by a research grant from Guidant, St. Paul, Minn., to the University of Rochester School of Medicine and Dentistry. Drs. Cannom, Daubert, and Higgins have given lectures sponsored by Guidant. PATIENTS DID NOT PAY FOR THE ICD DEVICE WAS PAID FOR BY GUIDANT
11.
12. Daubert, J. P. et al. J Am Coll Cardiol 2008;51:1357-1365 Survival Free of Inappropriate Shock/Therapy
13.
14. Consequences of (Mal)function: Proarrhythmia From Local Lead Effects? SLS sequence leads to induction of VTs Many of induced VTs originate from defib.electrode site(EP Proven)
17. Multivariate Proportional Hazards Regression Model: Risk of All-Cause Mortality in the Conventional Therapy Group for Selected Risk Factors Risk Factor HR 95% Confidence Interval p Value NYHA functional class >II 1.87 1.23–2.86 0.004 Atrial fibrillation 1.87 1.05–3.22 0.034 QRS >120 ms 1.65 1.08–2.51 0.020 Age >70 yrs 1.57 1.02–2.41 0.042 BUN >26 mg/dl (and <50 mg/dl) 1.56 1.00–2.42 0.048
18. Goldenberg, I. et al. J Am Coll Cardiol 2008;51:288-296 Risk stratification ICD vs. Conventional- Probability of Survival in Patients With Risk Scores 1, 2, and >=3
19. Goldenberg, I. et al. J Am Coll Cardiol 2008;51:288-296 Risk stratification ICD vs. Conventional- Probability of Survival in VHR Patients
20. Goldenberg, I. et al. J Am Coll Cardiol 2008;51:288-296 U-Shaped Curve for ICD Efficacy
21.
22.
23. Kaplan–Meier Estimates of the Cumulative Risk of Death from Any Cause. Hohnloser SH et al. N Engl J Med 2004;351:2481-2488.
25. Infrequent physician use of implantable cardioverter-defibrillators risks patient safety-New York state residents undergoing ICD implantation Stephen Lyman , Art Sedrakyan , Huong Do , Renee Razzano , Alvin I ushlin 2 Heart 2011;97:1655-1660
Figure 2. Kaplan–Meier Estimates of the Probability of Survival in the Group Assigned to Receive an Implantable Defibrillator and the Group Assigned to Receive Conventional Medical Therapy. The difference in survival between the two groups was significant (nominal P=0.007, by the log-rank test). Figure 3. Hazard Ratios and 95 Percent Confidence Intervals for Death from Any Cause in the Defibrillator Group as Compared with the Group Assigned to Receive Conventional Medical Therapy, According to Selected Clinical Characteristics. The hazard ratios in the various subgroups were similar, with no statistically significant interactions. The dotted vertical line represents the results for the entire study (nominal hazard ratio, 0.66, without adjustment for the stopping rule). The horizontal lines indicate nominal 95 percent confidence intervals. LVEF denotes left ventricular ejection fraction, and NYHA New York Heart Association.
Figure 1. Kaplan–Meier Estimates of the Cumulative Risk of Death from Any Cause, According to Study Group. ICD denotes implantable cardioverter–defibrillator.